Editing Ribavirin (section)

===Taribavirin===
{{main|Taribavirin}}
The most successful ribavirin derivative to date is the 3-carboxamidine derivative of the parent 3-carboxamide, first reported in 1973 by J. T. Witkowski et al.,<ref>{{cite journal | vauthors = Witkowski JT, Robins RK, Khare GP, Sidwell RW | title = Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides | journal = Journal of Medicinal Chemistry | volume = 16 | issue = 8 | pages = 935–937 | date = August 1973 | pmid = 4355593 | doi = 10.1021/jm00266a014 }}</ref> and now called [[taribavirin]] (former names "viramidine" and "ribamidine"). This drug shows a similar spectrum of antiviral activity to ribavirin, which is not surprising as it is now known to be a pro-drug for ribavirin. Taribavirin, however, has useful properties of less erythrocyte-trapping and better liver-targeting than ribavirin. The first property is due to taribavirin's basic amidine group which inhibits drug entry into RBCs, and the second property is probably due to increased concentration of the enzymes which convert amidine to amide in liver tissue.<ref>{{cite journal | vauthors = Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF | title = In vitro and in vivo influenza virus-inhibitory effects of viramidine | journal = Antiviral Research | volume = 68 | issue = 1 | pages = 10–17 | date = October 2005 | pmid = 16087250 | doi = 10.1016/j.antiviral.2005.06.003 }}</ref> Taribavirin completed [[Clinical trial#Phase III|phase III]] human trials in 2012.<ref>{{cite report |author=U.S. National Library of Medicine |date=2012-06-22 |title=Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive (VISER2) |url=https://clinicaltrials.gov/ct2/show/NCT00093093 |publisher=National Institutes of Health |access-date=2021-03-25}}</ref>

{{Clear}}